机构：[1]Tumor Molecular Laboratory, Zhejiang Rongjun Hospital, Jiaxing, China[2]Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[3]Pathology, Fujian Cancer Hospital, Fuzhou, China[4]Thoracic Medical Oncology II, Hunan Cancer Hospital, Changsha, China[5]Pathology, Daping Hospital and Research Institute of Surgery, Army Medical University, Chongqing, China[6]Oncology, Sun Yat-sen University Cancer Hospital, Guangzhou, China[7]Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China[8]Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, China[9]Lung Cancer, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China[10]Oncology, The Third People’s Hospital of Zhengzhou, Zhengzhou, China[11]Medical Oncology, Fujian Cancer Hospital, Fuzhou, China[12]Oncology, The Second Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, China[13]Oncology, Baotou Cancer Hospital, Baotou, China[14]Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[15]Radiotherapy, Xiamen Cancer Hospital, Xiamen, China[16]Oncology, Shanxi Dayi Hospital, Shanxi Academy of Medical Science, Taiyuan, China山西白求恩医院[17]Respiratory Medicine, Jinling Hospital, Nanjing, China
第一作者机构：[1]Tumor Molecular Laboratory, Zhejiang Rongjun Hospital, Jiaxing, China
推荐引用方式(GB/T 7714)：
Li X.,Wang W.,Xu C.,et al.A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing[J].ANNALS OF ONCOLOGY.2019,30:-.doi:10.1093/annonc/mdz437.052.
APA：
Li, X.,Wang, W.,Xu, C.,Pu, X.,Fang, S....&Song, Y..(2019).A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing.ANNALS OF ONCOLOGY,30,
MLA：
Li, X.,et al."A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing".ANNALS OF ONCOLOGY 30.(2019):-
医学